Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.2M | $89.9M | $2.90M | $220M | $493M | $844M | $1.04B | $1.83B | $2.25B | $3.71B |
| Revenue growth | — | 90.7% | -96.8% | 7477.6% | 124.3% | 71.3% | 22.9% | 76.2% | 23.0% | 65.2% |
| Operating income | -$425M | -$500M | -$815M | -$939M | -$828M | -$709M | -$785M | -$282M | -$177M | $502M |
| Operating margin | -900.3% | -556.2% | -28092.2% | -427.5% | -168.1% | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% |
| Net income | -$410M | -$491M | -$761M | -$886M | -$858M | -$853M | -$1.13B | -$440M | -$278M | $314M |
| Net margin | -869.6% | -545.9% | -26258.5% | -403.2% | -174.1% | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| EPS (diluted) | -$4.79 | -$5.42 | -$7.57 | -$8.11 | -$7.46 | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$308M | -$383M | -$563M | -$278M | -$615M | -$642M | -$541M | $104M | -$8.31M | $524M |
| Capital expenditures | $64.6M | $104M | $127M | $140M | $70.4M | $76.4M | $72.1M | $62.2M | $34.3M | $58.7M |
| Free cash flow | -$372M | -$487M | -$690M | -$419M | -$685M | -$718M | -$613M | $41.9M | -$42.6M | $465M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $194M | $645M | $420M | $547M | $497M | $820M | $866M | $813M | $966M | $1.66B |
| Total assets | $1.26B | $1.99B | $1.57B | $2.40B | $3.41B | $3.64B | $3.55B | $3.83B | $4.24B | $4.97B |
| Total liabilities | $343M | $228M | $273M | $956M | $2.39B | $3.06B | $3.70B | $4.05B | $4.17B | $4.18B |
| Shareholders' equity | $920M | $1.77B | $1.30B | $1.44B | $1.02B | $588M | -$158M | -$221M | $67.1M | $789M |
| Retained earnings | -$1.66B | -$2.15B | -$2.84B | -$3.73B | -$4.59B | -$5.44B | -$6.57B | -$7.01B | -$7.29B | -$6.70B |
| Shares (wtd avg diluted) | 85.9M | 99.7M | 101M | 109M | 115M | 118M | 122M | 125M | 128M | 135M |
Every figure is extracted from ALNYLAM PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.